Johnson & Johnson annual free cash flow per share
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Johnson & Johnson Free Cash Flow Per Share Growth & History (JNJ)
Johnson & Johnson's free cash flow per share was $8.18 for fiscal 2025.
View full Johnson & Johnson company overviewJohnson & Johnson annual free cash flow per share history
| Fiscal year | Period ended | Free cash flow per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-28 | $8.18 | -$0.06 | −0.73% |
| 2024 | 2024-12-29 | $8.24 | $1.04 | +14.44% |
| 2023 | 2023-12-31 | $7.20 | $0.66 | +10.03% |
| 2022 | 2023-01-01 | $6.55 | -$0.96 | −12.79% |
| 2021 | 2022-01-02 | $7.51 | -$0.16 | −2.11% |
| 2020 | 2021-01-04 | $7.67 | $0.14 | +1.83% |
| 2019 | 2019-12-29 | $7.53 | $0.62 | +8.96% |
| 2018 | 2018-12-30 | $6.91 | $0.31 | +4.65% |
| 2017 | 2017-12-31 | $6.60 | $0.93 | +16.31% |
| 2016 | 2017-01-01 | $5.68 | -$0.13 | −2.29% |
| 2015 | 2016-01-03 | $5.81 | $0.48 | +9.08% |
| 2014 | 2014-12-28 | $5.33 | $0.41 | +8.29% |
| 2013 | 2013-12-29 | $4.92 | $0.39 | +8.68% |
| 2012 | 2012-12-30 | $4.53 | $0.36 | +8.58% |
| 2011 | 2012-01-01 | $4.17 | -$0.92 | −18.08% |
| 2010 | 2011-01-02 | $5.09 | -$0.06 | −1.15% |
| 2009 | 2010-01-03 | $5.15 | $0.90 | +21.18% |
| 2008 | 2008-12-28 | $4.25 | $0.06 | +1.39% |
| 2007 | 2007-12-30 | $4.19 | — | — |
Johnson & Johnson quarterly free cash flow per share
Q3.08
Q1.09
Q2.09
Q3.09
Q1.10
Q2.10
Q3.10
Q1.11
Q2.11
Q3.11
Q1.12
Q2.12
Q3.12
Q1.13
Q2.13
Q3.13
Q1.14
Q2.14
Q3.14
Q1.15
Q2.15
Q3.15
Q1.16
Q2.16
Q3.16
Q1.17
Q2.17
Q3.17
Q1.18
Q2.18
Q3.18
Q1.19
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-28 | $3.03 | $1.85 | +157.20% |
| Q1 2026 | 2026-03-29 | $0.61 | -$0.80 | −56.67% |
| Q4 2025 | 2025-12-28 | $2.27 | — | — |
| Q3 2025 | 2025-09-28 | $3.33 | $0.43 | +15.00% |
| Q2 2025 | 2025-06-29 | $1.18 | -$0.76 | −39.11% |
| Q1 2025 | 2025-03-30 | $1.40 | $0.22 | +18.61% |
| Q3 2024 | 2024-09-29 | $2.89 | $0.31 | +11.91% |
| Q2 2024 | 2024-06-30 | $1.93 | $0.76 | +64.41% |
| Q1 2024 | 2024-03-31 | $1.18 | $0.26 | +28.80% |
| Q3 2023 | 2023-10-01 | $2.59 | $0.56 | +27.41% |
| Q2 2023 | 2023-07-02 | $1.18 | -$0.62 | −34.41% |
| Q1 2023 | 2023-04-02 | $0.92 | -$0.36 | −28.36% |
| Q3 2022 | 2022-10-02 | $2.03 | -$0.84 | −29.19% |
| Q2 2022 | 2022-07-03 | $1.79 | $0.08 | +4.94% |
| Q1 2022 | 2022-04-03 | $1.28 | -$0.01 | −0.65% |
| Q3 2021 | 2021-10-03 | $2.87 | -$0.04 | −1.35% |
| Q2 2021 | 2021-07-04 | $1.71 | $0.65 | +61.35% |
| Q1 2021 | 2021-04-04 | $1.29 | $0.25 | +24.39% |
| Q3 2020 | 2020-09-27 | $2.90 | $0.33 | +12.86% |
| Q2 2020 | 2020-06-28 | $1.06 | -$0.87 | −45.01% |
| Q1 2020 | 2020-03-29 | $1.04 | -$0.05 | −4.36% |
| Q3 2019 | 2019-09-29 | $2.57 | $0.54 | +26.64% |
| Q2 2019 | 2019-06-30 | $1.93 | -$0.01 | −0.68% |
| Q1 2019 | 2019-03-31 | $1.09 | -$0.01 | −1.28% |
| Q3 2018 | 2018-09-30 | $2.03 | -$0.01 | −0.37% |
| Q2 2018 | 2018-07-01 | $1.94 | $0.05 | +2.75% |
| Q1 2018 | 2018-04-01 | $1.10 | $0.23 | +26.43% |
| Q3 2017 | 2017-10-01 | $2.04 | $0.35 | +20.50% |
| Q2 2017 | 2017-07-02 | $1.89 | $0.50 | +36.17% |
| Q1 2017 | 2017-04-02 | $0.87 | $0.31 | +54.64% |
| Q3 2016 | 2016-10-02 | $1.69 | -$0.24 | −12.42% |
| Q2 2016 | 2016-07-03 | $1.39 | -$0.31 | −18.33% |
| Q1 2016 | 2016-04-03 | $0.56 | -$0.27 | −32.83% |
| Q3 2015 | 2015-09-27 | $1.93 | $0.55 | +39.38% |
| Q2 2015 | 2015-06-28 | $1.70 | $0.04 | +2.28% |
| Q1 2015 | 2015-03-29 | $0.84 | -$0.33 | −28.15% |
| Q3 2014 | 2014-09-28 | $1.39 | -$0.44 | −23.93% |
| Q2 2014 | 2014-06-29 | $1.66 | $0.14 | +8.98% |
| Q1 2014 | 2014-03-30 | $1.16 | $0.56 | +92.22% |
| Q3 2013 | 2013-09-29 | $1.82 | $0.26 | +16.96% |
| Q2 2013 | 2013-06-30 | $1.52 | $0.20 | +14.75% |
| Q1 2013 | 2013-03-31 | $0.61 | -$0.23 | −27.66% |
| Q3 2012 | 2012-09-30 | $1.56 | $0.13 | +9.08% |
| Q2 2012 | 2012-07-01 | $1.33 | $0.13 | +10.54% |
| Q1 2012 | 2012-04-01 | $0.84 | $0.15 | +22.03% |
| Q3 2011 | 2011-10-02 | $1.43 | -$0.21 | −12.74% |
| Q2 2011 | 2011-07-03 | $1.20 | -$0.01 | −0.80% |
| Q1 2011 | 2011-04-03 | $0.69 | -$0.51 | −42.55% |
| Q3 2010 | 2010-10-03 | $1.64 | -$0.02 | −1.34% |
| Q2 2010 | 2010-07-04 | $1.21 | $0.20 | +19.33% |
| Q1 2010 | 2010-04-04 | $1.20 | $0.33 | +38.19% |
| Q3 2009 | 2009-09-27 | $1.66 | $0.18 | +12.41% |
| Q2 2009 | 2009-06-28 | $1.01 | — | — |
| Q1 2009 | 2009-03-29 | $0.86 | — | — |
| Q3 2008 | 2008-09-28 | $1.48 | — | — |
Johnson & Johnson free cash flow per share trends
Over the last five fiscal years, Johnson & Johnson's free cash flow per share increased from $7.67 to $8.18, a change of $0.51. The latest reported quarter, Q2 2026, shows $3.03.
About the metric
What free cash flow per share means
Free cash flow per share estimates the free cash flow generated for each weighted-average common share. It combines operating cash generation, capital spending, and the share base into a per-share measure that can be compared over time.
Calculation and source
How free cash flow per share is calculated
TickerStat calculates free cash flow as operating cash flow minus capital expenditures, then divides it by basic weighted-average shares for the aligned fiscal period. Reliable filing-derived share counts are used when a filer omits the direct weighted-average-share fact. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Johnson & Johnson source filings ↗Community posts
J&J reports surgery-comparator benefit for Erleada in prostate cancer
Johnson & Johnson ($JNJ) reported new PROTEUS substudy results comparing Erleada plus hormone therapy before and after prostate surgery with surgery alone. Among 408 patients with high-risk localized or locally advanced disease, the regimen ...
J&J reports early prostate-cancer responses for experimental oral drug
Johnson & Johnson ($JNJ) disclosed early results for oral JNJ-6143 in heavily pretreated advanced prostate cancer. Among 31 evaluable patients receiving 50 milligrams, 77% achieved at least a 50% PSA decline. Confirmed tumor responses occur ...
Carvykti follow-up finds half of a small cohort progression-free at five years
Johnson & Johnson ($JNJ) and Legend Biotech ($LEGN) reported five-year follow-up from 20 patients in the Phase 2 CARTITUDE-2 Cohort A study of Carvykti. Ten remained alive without disease progression or further anti-myeloma treatment after ...
Johnson & Johnson says Tremfya meets axial psoriatic-arthritis trial goals
Johnson & Johnson ($JNJ) said Tremfya met the primary and key secondary endpoints in STAR, a randomized, double-blind Phase 4 study in patients with axial manifestations of psoriatic arthritis. The company reported improvement over placebo ...
Apollo reportedly nears $20 billion talks for J&J orthopedics business
Apollo ($APO) is in talks to acquire Johnson & Johnson’s ($JNJ) DePuy Synthes orthopedics business in a transaction that could be worth around $20 billion, Reuters reported, citing Bloomberg. The unit generated approximately $9.3 billion in ...
